About Xinvento
Xinvento is a Healthcare company based in Amsterdam (Netherlands) founded in 2021 by Sarah Hafith and Piet Wigerinck, and was acquired by Rhythm Pharmaceuticals in February 2023. Therapies for congenital hyperinsulinism are researched and developed. Xinvento offers products and services including CHI Treatment. Its focus areas include Life Sciences, Rare Diseases, Drugs and Endocrine Diseases. Its legal entity is Xinvento BV.
Company details
Xinvento was founded in 2021 and is based in Amsterdam, Netherlands. Focus is placed on the research and development of treatments for congenital hyperinsulinism, a rare disease marked by persistent hypoglycemia. Operations center on advancing therapies within the biotechnology sector to address this condition, with activities conducted primarily in Europe. Key personnel include co-founders Sarah Hafith and Piet Wigerinck.
- Headquarters Amsterdam, Netherlands
- Founders Sarah Hafith, Piet Wigerinck
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website xinvento.com
- Social LinkedIn X
- Acquired by Rhythm Pharmaceuticals (Feb 2023)
- Legal Name Xinvento Bv
- InvestorsRhythm Pharmaceuticals
& 8 more
- Acquired byRhythm Pharmaceuticals
(Feb 2023)
Products & Services of Xinvento
Xinvento offers a comprehensive portfolio of products and services, including CHI Treatment.
Developing alternative treatments to manage congenital hyperinsulinism symptoms effectively.
Funding Insights of Xinvento
- Total Rounds 1
- Investors Count 8
All 1 funding rounds of Xinvento with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | Seed | β | β |
9 investors in total: 1 institutional and 8 angel.
Investors in Xinvento
Xinvento has secured backing from 9 investors, including angel investors. Prominent investors backing the company include Rhythm Pharmaceuticals, Ed Kaye and John Maraganore.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EK Ed Kaye | unknown_5397146c8c7e42039 | |||
JM John Maraganore | unknown_e7c472b4a7e349b1a | |||
DM David Meeker | Angel investor focusing on Indian startups, limited public data available. | unknown_3e46cdae255f4b37a | ||
JS James Shannon | Angel investor focusing on Indian startups, tech enthusiast | unknown_52116cdd0fca49578 | ||
DD Daniel de Boer | Angel investor and entrepreneur, founder of Procol, focused on agritech and supply chain. | unknown_444acc65bcd342f79 | ||
DV Dinko Valerio | unknown_a1eaae42908e427db | |||
OV Onno van de Stolpe | Dutch biotech entrepreneur, angel investor, and founder of Galapagos NV. | unknown_95a84abc6d614243b | ||
HS Hans Schikan | Dutch biotech leader, angel investor in Indian health startups | unknown_254fc864cd1842f58 | ||
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | rhythmtx.com | Boston, United States |
Investor details for Xinvento
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xinvento
3 people are tracked at Xinvento (3 in leadership).
| Name | Role | Group |
|---|---|---|
Sarah Hafith | Co-Founder | Leadership |
Piet Wigerinck | Co-Founder | Leadership |
Claudine Van Der Sande | Founding CEO | Leadership |
Complete people profiles for Xinvento
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xinvento
3 dated milestones of Xinvento across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Xinvento is founded.
- Funding First funding round.
- Exit Acquired by Rhythm Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xinvento
Complete news archive for Xinvento
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xinvento
Xinvento was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Xinvento is headquartered in Amsterdam, Netherlands.
Xinvento was founded in 2021 and is based in Amsterdam, Netherlands. Focus is placed on the research and development of treatments for congenital hyperinsulinism, a rare disease marked by persistent hypoglycemia. Operations center on advancing therapies within the biotechnology sector to address this condition, with activities conducted primarily in Europe. Key personnel include co-founders Sarah Hafith and Piet Wigerinck.
Xinvento offers CHI Treatment.
Xinvento has 9 investors. Key investors include Rhythm Pharmaceuticals, Ed Kaye, John Maraganore, David Meeker, and James Shannon.
Xinvento operates through Xinvento Bv.
Yes. Xinvento was acquired by Rhythm Pharmaceuticals in February 2023.

